U.S. Markets open in 6 hrs 16 mins
  • S&P Futures

    3,782.00
    -21.25 (-0.56%)
     
  • Dow Futures

    30,217.00
    -148.00 (-0.49%)
     
  • Nasdaq Futures

    11,566.75
    -74.00 (-0.64%)
     
  • Russell 2000 Futures

    1,768.20
    -13.30 (-0.75%)
     
  • Crude Oil

    86.56
    +0.04 (+0.05%)
     
  • Gold

    1,732.60
    +2.10 (+0.12%)
     
  • Silver

    20.98
    -0.12 (-0.56%)
     
  • EUR/USD

    0.9969
    -0.0017 (-0.1695%)
     
  • 10-Yr Bond

    3.6170
    0.0000 (0.00%)
     
  • Vix

    29.07
    -1.03 (-3.42%)
     
  • GBP/USD

    1.1453
    -0.0021 (-0.1844%)
     
  • USD/JPY

    144.3730
    +0.1740 (+0.1207%)
     
  • BTC-USD

    20,236.30
    +366.90 (+1.85%)
     
  • CMC Crypto 200

    458.81
    +13.37 (+3.00%)
     
  • FTSE 100

    7,086.46
    0.00 (0.00%)
     
  • Nikkei 225

    27,120.53
    +128.32 (+0.48%)
     

Inari Medical to Host First Analyst & Investor Day

·2 min read
Inari Medical, Inc.
Inari Medical, Inc.

IRVINE, Calif., Sept. 02, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that its management team will host the Company’s first Analyst and Investor Day on Thursday, September 15, 2022 at its headquarters in Irvine, CA.

The Company will provide an update on the Inari’s business progress and plans via a webcast, which will commence at approximately 9 a.m. Pacific Time.

If you would like to participate in this event, please click here to pre-register.

A live webcast replay of the presentation may be accessed for 90 days on the “Investor Relations” section of the company’s website at: https://www.inarimedical.com/.

About Inari Medical, Inc.
Inari Medical, Inc. is a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases. Our current product offering consists of two minimally invasive, novel catheter-based mechanical thrombectomy devices that are designed to remove large clots from large vessels and eliminate the need for thrombolytic drugs. The company purpose-built its products for the specific characteristics of the venous system and the treatment of the two distinct manifestations of venous thromboembolism, or VTE: deep vein thrombosis and pulmonary embolism. The ClotTriever system is 510(k)-cleared by FDA and CE marked for the non-surgical removal of clot from peripheral blood vessels, including for the use in the treatment of deep vein thrombosis. The FlowTriever system is 510(k)-cleared by FDA and CE marked for the non-surgical removal of clot from peripheral blood vessels, including for the use in the treatment of pulmonary embolism and clot in transit in the right atrium.

Investor Contact:
ICR Westwicke
Caroline Corner
Phone +1-415-202-5678
caroline.corner@westwicke.com